Terminal Access

Unlimited access to the most powerful analytical tools in finance.

Bloomberg Fair Value
20M Securities
50Y History
10Y Estimates
8.000+ News Daily
Subscribe for $2
Overview
Profile

Beigene stock

6160.HK
KYG1146Y1017
A144EN

Price

19.26
Today +/-
-0.32
Today %
-1.85 %

Beigene stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Beigene stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Beigene stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Beigene stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Beigene's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Beigene Stock Price History

DateBeigene Price
4/25/202519.26 undefined
4/24/202519.62 undefined
4/23/202519.52 undefined
4/22/202519.27 undefined
4/17/202517.99 undefined
4/16/202518.06 undefined
4/15/202518.69 undefined
4/14/202519.10 undefined
4/11/202517.63 undefined
4/10/202516.88 undefined
4/9/202516.71 undefined
4/8/202517.06 undefined
4/7/202516.18 undefined
4/3/202520.94 undefined
4/2/202521.15 undefined
4/1/202521.95 undefined
3/31/202521.39 undefined
3/28/202520.77 undefined

Beigene Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Beigene, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Beigene from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Beigene’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Beigene. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Beigene’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Beigene’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Beigene’s growth potential.

Beigene Revenue, EBIT and net profit per share

DateBeigene RevenueBeigene EBITBeigene Net Income
2030e69.98 B undefined0 undefined413.98 B undefined
2029e63.33 B undefined15.94 B undefined313.96 B undefined
2028e57.32 B undefined11.67 B undefined246.82 B undefined
2027e48.89 B undefined7.83 B undefined14.05 B undefined
2026e43.85 B undefined3.02 B undefined6.91 B undefined
2025e36.61 B undefined542.76 M undefined931.75 M undefined
2024e26.84 B undefined-3.71 B undefined-5.99 B undefined
202317.42 B undefined-8.75 B undefined-6.72 B undefined
20229.57 B undefined-12.03 B undefined-13.64 B undefined
20217.59 B undefined-9.47 B undefined-9.75 B undefined
20202.12 B undefined-11.36 B undefined-11.38 B undefined
20192.95 B undefined-6.8 B undefined-6.91 B undefined
20181.31 B undefined-4.83 B undefined-4.75 B undefined

Beigene Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
SHARES (B)
DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e2030e
1.312.952.127.599.5717.4226.8436.6143.8548.8957.3263.3369.98
-125.50-28.23257.9226.0782.1354.0236.4119.7911.5017.2310.4910.50
85.5083.3477.0886.0280.1184.4554.8340.1933.5530.0925.6723.2321.02
1.122.461.636.537.6614.710000000
-4.75-6.91-11.38-9.75-13.64-6.72-5.990.936.9114.05246.82313.96413.98
-45.6864.64-14.3739.96-50.78-10.75-115.53642.21103.271,657.2427.2031.86
1.331.331.331.331.341.360000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Beigene Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Beigene is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (M)
INVENTORIES (B)
OTHER CURRENT LIAB. (B)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (k)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (k)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (B)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (B)
PROVISIONS (B)
OTHER SHORT-TERM LIAB. (B)
SHORT-TERM DEBTS (B)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (M)
OTHER LIAB. (B)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
201820192020202120222023
           
12.276.8630.3942.2131.4522.55
0.340.490.393.081.22.54
90.3988.55182.81448.75231.41685.62
0.110.20.581.551.952.95
0.550.530.791.251.341.08
13.368.1832.3448.5436.1729.81
1.071.872.564.056.129.32
00321.96642.58637.82635.22
113.41230.55139.09150.9651.0771.73
311.13351.74348.21666.15715.06982.34
7097097097097090
0.640.60.861.140.530.3
2.133.054.226.648.0511.31
15.4911.2236.5655.1844.2241.12
           
512527796890904906
20.9522.554.0678.8180.5281.38
-9,284.26-16,198.89-27,582.69-37,330.36-50,972.41-57,688.27
0.40.47-1.14-1.530.841.4
000-24.7-54.189.01
12.066.7725.3439.9330.3325.1
0.871.012.132.592.483.68
0.290.410.781.181.682.57
0.480.671.913.663.671.54
002.12.622.24.68
6075.4491.92157.76263.86358.79
1.72.167.0110.210.312.83
0.280.761.391.561.681.56
00022.0445.9256.17
1.351.422.823.471.861.57
1.632.184.215.053.593.19
3.334.3411.2315.2613.8916.02
15.411.1236.5655.1844.2241.12
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Beigene provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Beigene's financial health and stability.

Assets

Beigene's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Beigene must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Beigene after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Beigene's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (B)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (B)
NET CHANGE IN EQUITY (B)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
nullnullnullnullnull20182019202020212022
-7-18-57-119-93000-1,413-2,003
111140004563
0000-5000-412
7-121457-1,504-2,924-236-7,253-9,674
29131349000186308
000010002925
000029-75-89-221-332-123
4-8-39-8912-4,200-5,546-5,179-8,284-7,799
00-5-23-58-721-618-992-2,256-2,334
0-0.03-0.06-0.22-0.36-4.525.08-21.863.132.41
0-0.03-0.05-0.2-0.3-3.85.7-20.865.394.75
0000000000
00.020.010.010.130.220.241.950.66-0.43
00.040.10.370.340003.540.05
00.050.10.380.4911.060.5931.3722.87-0.45
0-00-00.0110.840.3529.4222.40.15
00000000-192-163
00.0100.070.15-0.21-2.38-0.4816.98-3.77
00000-4,921.63-6,164.34-6,171.61-10,541.06-10,134.36
0000000000

Beigene stock margins

The Beigene margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Beigene. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Beigene.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Beigene's sales revenue. A higher gross margin percentage indicates that the Beigene retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Beigene's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Beigene's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Beigene's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Beigene. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Beigene's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Beigene Margin History

Beigene Gross marginBeigene Profit marginBeigene EBIT marginBeigene Profit margin
2030e84.45 %0 %591.54 %
2029e84.45 %25.18 %495.75 %
2028e84.45 %20.37 %430.6 %
2027e84.45 %16.01 %28.73 %
2026e84.45 %6.89 %15.76 %
2025e84.45 %1.48 %2.55 %
2024e84.45 %-13.84 %-22.33 %
202384.45 %-50.22 %-38.55 %
202280.1 %-125.71 %-142.6 %
202186.02 %-124.77 %-128.45 %
202077.09 %-535.92 %-536.92 %
201983.38 %-230.07 %-234.08 %
201885.52 %-368.81 %-362.35 %

Beigene Stock Sales Revenue, EBIT, Earnings per Share

The Beigene earnings per share therefore indicates how much revenue Beigene has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Beigene earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Beigene's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Beigene’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Beigene's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Beigene Revenue, EBIT and net profit per share

DateBeigene Sales per ShareBeigene EBIT per shareBeigene Earnings per Share
2030e26.11 undefined0 undefined154.47 undefined
2029e23.63 undefined0 undefined117.16 undefined
2028e21.39 undefined0 undefined92.1 undefined
2027e18.24 undefined0 undefined5.24 undefined
2026e16.36 undefined0 undefined2.58 undefined
2025e13.66 undefined0 undefined0.35 undefined
2024e10.01 undefined0 undefined-2.24 undefined
202312.84 undefined-6.45 undefined-4.95 undefined
20227.14 undefined-8.97 undefined-10.18 undefined
20215.69 undefined-7.09 undefined-7.3 undefined
20201.59 undefined-8.51 undefined-8.53 undefined
20192.21 undefined-5.09 undefined-5.18 undefined
20180.98 undefined-3.62 undefined-3.56 undefined

Beigene business model

Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.com.

Beigene SWOT Analysis

Strengths

Beigene Ltd has a strong portfolio of oncology drug candidates, which positions the company well in the growing market for cancer treatments.

The company has established partnerships with major international pharmaceutical companies, enabling it to access resources and expertise that can help accelerate drug development and commercialization.

Beigene Ltd has a strong financial position, with a solid cash reserve and access to capital markets, providing the necessary resources for research and development, as well as potential acquisitions.

Weaknesses

The company heavily relies on a few key drug candidates, which poses a risk in case of any setbacks in the clinical trials or regulatory approval processes.

Beigene Ltd currently has a limited presence in international markets, particularly outside of Asia, which may restrict its commercial opportunities and revenue potential.

The company may face challenges in effectively managing its rapid growth, including scaling up its operations and maintaining a cohesive organizational culture.

Opportunities

The increasing prevalence of cancer globally presents a significant growth opportunity for Beigene Ltd, given its focus on oncology therapeutics.

Expansion into new markets, such as Europe and the United States, can provide access to larger patient populations and enhance the company's revenue potential.

Collaborations with academic institutions and research organizations can foster innovation and help Beigene Ltd stay at the forefront of cancer research and development.

Threats

Intense competition within the oncology drug market from both established pharmaceutical companies and emerging biotech firms can limit Beigene Ltd's market share and pricing power.

Evolving regulatory requirements and the potential for delays in drug approvals can hinder the company's ability to bring new therapeutics to market in a timely manner.

The possibility of unforeseen adverse events during clinical trials or safety concerns post-commercialization can impact the company's reputation and investor confidence.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Beigene Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Beigene historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Beigene shares outstanding

The number of shares was Beigene in 2024 — This indicates how many shares 1.357 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Beigene earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Beigene's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Beigene’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Beigene's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Beigene.

Eulerpool ESG Scorecard© for the Beigene stock

Eulerpool World ESG Rating (EESG©)

86/ 100

🌱 Environment

75

👫 Social

99

🏛️ Governance

83

Environment

Scope 1 - Direct Emissions
3,391
Scope 2 - Indirect emissions from purchased energy
53,870
Scope 3 - Indirect emissions within the value chain
217,158
Total CO₂ emissions
57,261
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees58.5
Percentage of women in management
Percentage of Asian employees37.2
Share of Asian management34.8
Percentage of Hispanic/Latino employees5.1
Hispano/Latino Management share6.7
Percentage of Black employees6.1
Black Management Share6.5
Percentage of white employees48.3
White Management Share48.6
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Beigene shareholders

%
Name
Stocks
Change
Date
0.17876 % Guangzhou High-tech Zone Technology Holdings Group Co., Ltd.4,790,45409/30/2024
0.17876 % SDIC Chuangyi Industrial Fund Management Co., Ltd.4,790,45409/30/2024
0.11194 % Wanjia Asset Management Co., Ltd.3,000,000-1,000,0009/30/2024
0.09702 % ICBC Credit Suisse Asset Management Co. Ltd.2,600,122800,1229/30/2024
0.08518 % China Universal Asset Management Co., Ltd.2,282,614616,1296/30/2024
0.08254 % Bank of China Investment Management Co., Ltd.2,211,963-805,1976/30/2024
0.08072 % China Asset Management Co., Ltd.2,163,2481,058,7626/30/2024
0.06455 % CIB Fund Management Co., Ltd.1,729,818446,8196/30/2024
0.06023 % Ninety One UK Limited1,614,223-31,56612/31/2024
0.05749 % China Insurance Investment Co., Ltd.1,540,665-257,2119/30/2024
1
2
3
4
5
...
10

Beigene Executives and Management Board

Mr. John Oyler

(56)
Beigene Co-Founder, Executive Chairman of the Board, Chief Executive Officer (since 2010)
Compensation 16.74 M

Dr. Xiaodong Wang

(61)
Beigene Co-Founder, Non-Executive Director
Compensation 4.27 M

Mr. Anthony Hooper

(69)
Beigene Non-Executive Independent Director
Compensation 518,000

Dr. Han Dugan

(67)
Beigene Non-Executive Independent Director
Compensation 516,000

Dr. Corazon Sanders

(67)
Beigene Non-Executive Independent Director
Compensation 507,000
1
2
3
4

Most common questions regarding Beigene

What values and corporate philosophy does Beigene represent?

Beigene Ltd represents values of scientific innovation, patient-centricity, and global collaboration. With a strong corporate philosophy, Beigene prioritizes the discovery and development of innovative medicines to address unmet medical needs. They aim to improve patient outcomes by advancing targeted therapies and immunotherapies. Beigene believes in collaboration with academic institutions, industry partners, and healthcare stakeholders to accelerate scientific breakthroughs and improve healthcare worldwide. By embracing a patient-centric approach, Beigene strives to provide accessible treatments and optimal care. Overall, Beigene Ltd demonstrates a commitment to scientific advancement, patient well-being, and global partnerships in their mission to transform the lives of patients with cancer and other serious diseases.

In which countries and regions is Beigene primarily present?

Beigene Ltd is primarily present in several countries and regions. The company has a significant presence in China, where it is headquartered and operates various research and development facilities. Additionally, Beigene Ltd has expanded its reach and established a global presence by conducting clinical trials and collaborations in countries such as the United States, Australia, Canada, and certain European countries. With its focus on biopharmaceuticals, Beigene Ltd strives to enhance cancer treatment options and improve the lives of patients worldwide through its presence in multiple countries and regions around the globe.

What significant milestones has the company Beigene achieved?

Beigene Ltd has achieved several significant milestones. In December 2015, the company secured a collaboration agreement with Celgene Corporation for the development and commercialization of cancer treatments in China. This partnership marked a major milestone in Beigene's efforts to provide innovative therapies to Chinese patients. In 2017, Beigene obtained its first drug approval in China for BTK inhibitor Brukinsa, offering a targeted treatment for certain types of lymphoma. Another important milestone was the successful completion of IPOs on both the Hong Kong and Nasdaq stock exchanges in 2018, which provided Beigene with additional financial resources to advance its pipeline.

What is the history and background of the company Beigene?

BeiGene Ltd is a renowned pharmaceutical company founded in 2010 in Beijing, China. The company focuses on developing and commercializing innovative medicines to meet various unmet medical needs globally. BeiGene's commitment lies in advancing breakthrough science and technologies to improve patients' lives. Since its establishment, the company has achieved significant milestones, including numerous successful clinical trials, regulatory approvals, and strategic collaborations. With a passionate team and robust pipeline, BeiGene is dedicated to discovering, developing, manufacturing, and commercializing high-quality medicines to address various diseases and improve healthcare outcomes worldwide.

Who are the main competitors of Beigene in the market?

The main competitors of Beigene Ltd in the market include multinational pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Merck & Co., and Novartis. These companies are also involved in developing and commercializing innovative medicines and therapies. Beigene Ltd faces competition in various therapeutic areas, including oncology and immuno-oncology, where it strives to excel through its research and development efforts and strategic partnerships. Ultimately, Beigene Ltd aims to establish a strong presence and gain a competitive edge in the global biopharmaceutical industry.

In which industries is Beigene primarily active?

Beigene Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Beigene?

The business model of Beigene Ltd is focused on developing and commercializing innovative oncology drugs. As a leading biotechnology company, Beigene aims to discover and develop high-quality therapies to address unmet medical needs in the field of cancer. By leveraging its expertise in drug discovery, clinical development, and commercialization, Beigene strives to improve patient outcomes and transform the lives of people affected by cancer. Through strategic collaborations, partnerships, and a diversified product pipeline, Beigene is committed to advancing novel therapies that can make a significant impact on cancer treatment.

What is the P/E ratio of Beigene 2025?

The Beigene P/E ratio is 28.04.

What is the P/S ratio of Beigene 2025?

The Beigene P/S ratio is 0.71.

What is the Quality Investing of Beigene?

The Quality Investing for Beigene is 3/10.

What is the revenue of Beigene 2025?

The expected Beigene revenue is 36.61 B USD.

How high is the profit of Beigene 2025?

The expected Beigene profit is 931.75 M USD.

What is the business model of Beigene

Beigene Ltd is a biotechnology company aimed at developing and commercializing innovative cancer therapies. The company was founded in 2010 and is headquartered in Beijing, China. Beigene specializes in the discovery, development, and commercialization of cancer drugs and has built an extensive portfolio of medications in recent years. Beigene's business model includes five main components. Firstly, the company conducts extensive research and development in all aspects of cancer treatment. It employs a variety of experts in its production facilities in China and the United States to develop drugs for different types of cancer. The company particularly focuses on developing drugs for solid tumors, hematological malignancies, and cancer immunotherapies. Secondly, Beigene collaborates with various players in the biotechnology industry to further develop its products and research. The company has established partnerships with leading universities, research institutions, and other companies in the industry. These partnerships have helped expand the company's portfolio and strengthen its ability to develop new cancer medications. Thirdly, Beigene has launched a wide range of cancer drugs that can be used to combat tumors in various types of cancer. Beigene has a number of medications in different phases of clinical trials, including already approved therapies for cancer. In addition to its own drug candidates, Beigene also works with partners to strengthen its pipeline and make progress in developing new cancer therapies both in China and overseas. Fourthly, Beigene has also presented opportunities for partnerships to commercialize its cancer drugs. The company has worked with some of the top pharmaceutical companies worldwide to bring some of its cancer medications to other countries. Beigene will enter into agreements and transfer licensing rights to other pharmaceutical companies to establish partnerships and ensure optimal commercialization of its medications. Fifthly, Beigene has excellent leaders and employees who support the company in achieving its goals. Since its founding, the company has experienced significant growth and has consistently engaged in innovative research and development. Furthermore, the company has followed a specific path in marketing its medications to achieve global reach as much as possible. Overall, Beigene's business model is a combination of intensive research and development, collaboration with other players in the industry, commercialization of cancer drugs, and outstanding personnel. The company is on track to become a key player in the field of cancer therapies and potentially contribute to finding a cure through its great success.

What is the Beigene dividend?

Beigene pays a dividend of 0 USD distributed over payouts per year.

How often does Beigene pay dividends?

The dividend cannot currently be calculated for Beigene or the company does not pay out a dividend.

What is the Beigene ISIN?

The ISIN of Beigene is KYG1146Y1017.

What is the Beigene WKN?

The WKN of Beigene is A144EN.

What is the Beigene ticker?

The ticker of Beigene is 6160.HK.

How much dividend does Beigene pay?

Over the past 12 months, Beigene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Beigene is expected to pay a dividend of 0 USD.

What is the dividend yield of Beigene?

The current dividend yield of Beigene is .

When does Beigene pay dividends?

Beigene pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Beigene?

Beigene paid dividends every year for the past 0 years.

What is the dividend of Beigene?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Beigene located?

Beigene is assigned to the 'Health' sector.

Wann musste ich die Aktien von Beigene kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Beigene from 4/27/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/27/2025.

When did Beigene pay the last dividend?

The last dividend was paid out on 4/27/2025.

What was the dividend of Beigene in the year 2024?

In the year 2024, Beigene distributed 0 USD as dividends.

In which currency does Beigene pay out the dividend?

The dividends of Beigene are distributed in USD.

All fundamentals about Beigene

Our stock analysis for Beigene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beigene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.